| Literature DB >> 25435950 |
Yong-Bao Wei1, Yun-Liang Gao1, Hong-Tao Wu1, Shi-Feng Ou-Yang1, Tao Xu1, Dong-Fang Mao1, Jin-Rui Yang1.
Abstract
Adrenocortical carcinoma (ACC) is a rare, but highly aggressive type of tumor with an incidence of one to two per million annually. Adrenocortical carcinosarcoma is an exceptional variant of ACC, which is characterized by the presence of histological regions of carcinoma and sarcoma. To date, to the best of our knowledge, there have only been 12 reported cases of adrenocortical carcinosarcoma. In the present study, a case of primary, non-functional adrenocortical carcinosarcoma is described, as well as a review of the literature to raise awareness of this particularly rare type of malignant neoplasm that is associated with a worse diagnosis and prognosis than adrenocortical carcinoma. In the present study, the patient underwent a laparoscopic left adrenalectomy and the tumor was dissected without complication from the left kidney. Microscopic observations showed the tumor comprised of epithelial and spindle cell components. The patient did not exhibit signs of tumor recurrence at the one-month follow-up. The potential diagnosis of adrenocortical carcinosarcoma must be considered when diagnosing adrenal malignancies in adults. In addition, comphrensive imunohistochemical staining may be required to identify possible sarcomatous patterns. To the best of our knowledge, the present case is the first to report an incidence of adrenocortical carcinosarcoma in China. Details of the patient are presented and the pathology of adrenocortical carcinosarcoma is discussed.Entities:
Keywords: adrenocortical carcinoma; adrenocortical carcinosarcoma; pathology
Year: 2014 PMID: 25435950 PMCID: PMC4247116 DOI: 10.3892/ol.2014.2635
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1Gross images and hematoxylin and eosin (H&E)-stained microscopic images of the primary adrenocortical carcinosarcoma. (A) A computed tomography scan demonstrates a 7.6×5.1-cm well-demarcated and peripherally enhanced left adrenal mass impinging on the pancreas and the spleen, without parenchymal invasion into the kidney. (B) Gross image of the cut surface of the adrenocortical carcinosarcoma shows a circumscribed mass, predominantly comprising paler, firm tissue, with partially yellow tissue. (C) A compressed rim of normal adrenal gland is apparent adjacent to the tumor capsule. (D) The tumor comprises of spindle cell and epithelial components (H&E staining; magnification, ×100). (E) Carcinomatous cells exhibit highly atypical nuclei and an abundant eosinophilic cytoplasm (H&E staining; magnification, ×200). (F) Spindle-shaped tumor cells reveal highly pleomorphic nuclei (H&E staining; magnification, ×200).
Figure 2Immunohistochemical staining of the primary adrenocortical carcinosarcoma. (A) Carcinomatous and sarcomatous cells positive for cluster of differentiation 56 (magnification, ×200). Cytoplasm of the sarcomatous cells positive for (B) Bcl-2 (magnification, ×200) and (C) neuron specific enolase (magnification, ×100). (D) Carcinomatous and sarcomatous cells positive for Ki-67 (x100).
Clinical and pathological features of previously reported cases of adrenocortical carcinosarcoma.
| Ref. | Author, year | Age, years/gender | Clinical presentation | Endocrine dysfunction | Location | Size/weight | Sarcomatous component | Immunostaining results | Total number of antibodies | POS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Caricinomatous | Sarcomatous | ||||||||||
| Okazumi | 46/M | Abdominal distention | No | R | 14 cm, 880 g | Spindle cell | NA | NA | NA | 6 months | |
| Collina | 68/F | Abdominal discomfort | No | L | 11 cm | Spindle cell | Low molecular weight CK, Vim | Low molecular weight CK, Vim | 7 | 6 months | |
| Decorato | 42/F | Abdominal pain | No | L | 19 cm, 1400 g | Rhabdo-myosarcoma | - | muscle specific actin | 5 | 7 months | |
| Fischler | 29/F | ↓ Weight, virilization | Yes | L | 12.5 cm, 610 g | Rhabdo-myosarcoma | Vim, | Vim, HHF and desmin | 5 | 8 months | |
| Barksdale | 79/F | Hypertension | Yes | R | 9 cm, 199 g | Osteosarcoma, chondrosarcoma | Vim | Vim | 5 | NA | |
| Lee | 61/M | Flank pain | Yes | R | 12 cm | Spindle cell | CK, focal NSE | CK, Vim | 10 | 2 days | |
| Sturm | 31/M | Abdominal pain | No | L | 12 cm, 620 g | Spindle cell | CD56, Vim, focal desmin, CK AE1/AE3, α-inhibin, Syn | CD56, Vim, focal desmin, HHF35 | 17 | 3 months | |
| Coli | 75/F | Abdominal pain | No | L | 15 cm | Spindle cell | CK (MNF-16), Vim, S-100, melan-A, focal HMB-45 | Vim, SMA, desmin, caldesmon, myogenin | 20 | 12 months | |
| Sasaki | 45/M | Abdominal pain | No | L | 17 cm, 2974 g | Rhabdo-myosarcoma | Vim, Syn, melan-A, and calretinin | Vim, Syn, melan-A, and calretinin; desmin, myogenin, myoglobin | 15 | 3 months | |
| Bertolini | 23/F | Fatigue, ↓ appetite, fixed mass in rectum | No | L | 14 cm | Osteosarcomatous | Inhibin, calretinin | - | NA | 14 months | |
| Thway | 45/M | Bloating, back pain | No | L | 24 cm, 6500 g | Rhabdo-myosarcoma | Melan-A, CD56, MNF116 | Desmin, myogenin | 28 | 11 months | |
| Kao | 45/M | Abdominal pain, weight loss | No | R | 15 cm, 760 g | Spindle cells, undifferentiated | melan-A, inhibin, calretinin, AE1/AE3, Syn, Vim, | Vim, NSE, FLI-1; Undifferentiated: CD99 | 18 | 7 months ; alive | |
| Current study | Wei | 63/F | Fatigue, flank pain | No | L | 8 cm | Spindle cells | NSE, FLI-1 | CD56, Bcl-2, NSE, Ki-67 | 11 | 1 month ; alive |
M, Male; F, Female; R, right; L, left; NA, not available; CK, cytokeratin; Vim, vimentin; -, negative, no carcinomatous or sarcomatous regions; NSE, neuron specific enolase; CD, cluster of differentiation; Syn, synaptophysin; POS, postoperative survival.
Immunohistochemical results (not including cytokeratins) of the reported adrenocortical carcinosarcoma.
| A, Carcinomatous component | |||
|---|---|---|---|
|
| |||
| Antibody | Check sum | Positive | Positive rate |
| FLI-1 | 1 | 1 | 100 |
| Melan-A | 5 | 4 | 80 |
| Vimentin | 9 | 7 | 78 |
| CD56 | 4 | 3 | 75 |
| Inhibin | 6 | 3 | 50 |
| Ki-67 | 2 | 1 | 50 |
| Syn | 7 | 3 | 43 |
| NSE | 5 | 2 | 40 |
| HMB-45 | 5 | 1 | 20 |
| Desmin | 7 | 1 | 14 |
| S-100 | 8 | 1 | 13 |
|
| |||
| B, Sarcomatous component | |||
|
| |||
| Antibody | Check sum | Positive | Positive rate |
|
| |||
| HHF | 3 | 3 | 100 |
| Bcl-2 | 1 | 1 | 100 |
| FLI-1 | 1 | 1 | 100 |
| Vimentin | 9 | 8 | 89 |
| Desmin | 7 | 5 | 71 |
| CD56 | 4 | 2 | 50 |
| Caldesmon | 2 | 1 | 50 |
| Ki-67 | 2 | 1 | 50 |
| Myoglobin | 2 | 1 | 50 |
| Myogenin | 5 | 2 | 40 |
| NSE | 5 | 2 | 40 |
| Calretinin | 5 | 1 | 20 |
| Melan-A | 5 | 1 | 20 |
| SMA | 6 | 1 | 17 |
| Syn | 7 | 1 | 14 |
CD, cluster of differentiation; Syn, synaptophysin; NSE, neuron specific enolase; HMB-45, human melanoma black 45; SMA, smooth muscle actin.